Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Tomoki TamuraKiichiro NinomiyaToshio KuboShoichi KuyamaSayaka TachibanaKoji InoueKenichi ChikamoriKenichiro KudoNobuaki OchiDaijiro HaradaYoshinobu MaedaKatsuyuki KiuraPublished in: Thoracic cancer (2021)
Anti-SARS-CoV-2 mRNA vaccination tends to be safe, but fever following vaccination tends to be more common among patients undergoing lung cancer treatment than among healthy individuals.